首页 > 最新文献

Dermatology Research and Practice最新文献

英文 中文
Pruritus in Hemodialysis Patients in a Sub-Saharan African Country: Benin-Associated Skin Conditions and Other Factors in 2023 in Three Hemodialysis Centers. 撒哈拉以南非洲国家血液透析患者的瘙痒症:2023年三个血液透析中心贝宁相关皮肤状况和其他因素
IF 1.9 Q3 DERMATOLOGY Pub Date : 2026-03-09 eCollection Date: 2026-01-01 DOI: 10.1155/drp/4482167
Dégboé Bérénice, Tounouga Dahlia Noelle, Gbénou Fabrice Mahouéna, Lossou Eric, Hazoumè Rodrigue, Vigan Jacques, Atadokpèdé Félix

Introduction: Pruritus is a frequent and debilitating complication in hemodialysis patients. Its pathophysiology remains poorly understood. This study aimed to describe the factors associated with pruritus in three hemodialysis centers in 2023.

Methods: This was a prospective, descriptive, and analytical cross-sectional study. It included 245 patients aged 18 years and older, undergoing hemodialysis for at least three months, hemodynamically stable, and who had provided informed consent. Pruritus intensity was assessed using the Itch-Numeric Rating Scale (Itch-NRS). Statistical analysis was performed using Stata 17, with a significance level set at p < 0.05.

Results: The prevalence of pruritus among hemodialysis patients was 40.41%. The mean age of participants was 52.75 years, with a sex ratio of 1.78. Pruritus was most often mild to moderate (90.91%), generalized (48.48%), or diffuse (51.52%) and had been present for at least 1 year in 67.67% of cases. The most frequently associated dermatoses were xeroderma (88.88%), nail abnormalities (77.14%), and diffuse hyperpigmentation (27.27%).Univariate analysis identified protective factors such as vitamin D supplementation, absence of anuria, absence of diffuse skin hyperpigmentation, absence of alopecia, and absence of nail abnormalities (p = 0.003-0.042; OR = 0.17-0.58). Multivariate analysis showed that prolonged duration of hemodialysis, the use of an arteriovenous fistula, severe xeroderma, and the presence of Beau's lines (p ≤ 0.039) increased the risk of pruritus in hemodialysis patients. Conversely, the use of oral antidiabetic agents was significantly associated with a reduced risk of pruritus (p = 0.003; OR = 0.25).

Conclusion: Pruritus is a common and chronic condition in hemodialysis patients, adversely affecting their quality of life. The main risk factors identified were severe xeroderma, prolonged duration of hemodialysis, use of an arteriovenous fistula, and the presence of Beau's lines, whereas the use of oral antidiabetic medications appeared to be protective. A better understanding of the pathophysiology of pruritus in hemodialysis patients could help improve its management and enhance patient comfort.

简介:瘙痒是血液透析患者中一种常见且使人衰弱的并发症。其病理生理学仍然知之甚少。本研究旨在描述2023年三个血液透析中心的瘙痒相关因素。方法:这是一项前瞻性、描述性和分析性的横断面研究。该研究包括245名18岁及以上的患者,接受血液透析至少3个月,血液动力学稳定,并提供知情同意。使用瘙痒数字评定量表(瘙痒- nrs)评估瘙痒强度。采用Stata 17进行统计学分析,显著性水平为p < 0.05。结果:血透患者瘙痒的发生率为40.41%。参与者的平均年龄为52.75岁,性别比为1.78。瘙痒多为轻至中度(90.91%),广泛性(48.48%)或弥漫性(51.52%),67.67%的病例至少存在1年。最常见的相关皮肤病是干皮病(88.88%)、指甲异常(77.14%)和弥漫性色素沉着(27.27%)。单因素分析确定了维生素D补充、无尿、无弥漫性皮肤色素沉着、无脱发和无指甲异常等保护因素(p = 0.003-0.042; OR = 0.17-0.58)。多因素分析显示,延长血液透析时间、使用动静脉瘘、严重的干皮病和Beau线的存在(p≤0.039)增加了血液透析患者瘙痒的风险。相反,口服降糖药的使用与瘙痒风险的降低显著相关(p = 0.003; OR = 0.25)。结论:皮肤瘙痒是血液透析患者常见的慢性疾病,严重影响患者的生活质量。确定的主要危险因素是严重的干皮病、血液透析持续时间延长、使用动静脉瘘和博氏线的存在,而使用口服抗糖尿病药物似乎具有保护作用。更好地了解血液透析患者瘙痒的病理生理,有助于改善其管理,提高患者的舒适度。
{"title":"Pruritus in Hemodialysis Patients in a Sub-Saharan African Country: Benin-Associated Skin Conditions and Other Factors in 2023 in Three Hemodialysis Centers.","authors":"Dégboé Bérénice, Tounouga Dahlia Noelle, Gbénou Fabrice Mahouéna, Lossou Eric, Hazoumè Rodrigue, Vigan Jacques, Atadokpèdé Félix","doi":"10.1155/drp/4482167","DOIUrl":"https://doi.org/10.1155/drp/4482167","url":null,"abstract":"<p><strong>Introduction: </strong>Pruritus is a frequent and debilitating complication in hemodialysis patients. Its pathophysiology remains poorly understood. This study aimed to describe the factors associated with pruritus in three hemodialysis centers in 2023.</p><p><strong>Methods: </strong>This was a prospective, descriptive, and analytical cross-sectional study. It included 245 patients aged 18 years and older, undergoing hemodialysis for at least three months, hemodynamically stable, and who had provided informed consent. Pruritus intensity was assessed using the Itch-Numeric Rating Scale (Itch-NRS). Statistical analysis was performed using Stata 17, with a significance level set at <i>p</i> < 0.05.</p><p><strong>Results: </strong>The prevalence of pruritus among hemodialysis patients was 40.41%. The mean age of participants was 52.75 years, with a sex ratio of 1.78. Pruritus was most often mild to moderate (90.91%), generalized (48.48%), or diffuse (51.52%) and had been present for at least 1 year in 67.67% of cases. The most frequently associated dermatoses were xeroderma (88.88%), nail abnormalities (77.14%), and diffuse hyperpigmentation (27.27%).Univariate analysis identified protective factors such as vitamin D supplementation, absence of anuria, absence of diffuse skin hyperpigmentation, absence of alopecia, and absence of nail abnormalities (<i>p</i> = 0.003-0.042; OR = 0.17-0.58). Multivariate analysis showed that prolonged duration of hemodialysis, the use of an arteriovenous fistula, severe xeroderma, and the presence of Beau's lines (<i>p</i> ≤ 0.039) increased the risk of pruritus in hemodialysis patients. Conversely, the use of oral antidiabetic agents was significantly associated with a reduced risk of pruritus (<i>p</i> = 0.003; OR = 0.25).</p><p><strong>Conclusion: </strong>Pruritus is a common and chronic condition in hemodialysis patients, adversely affecting their quality of life. The main risk factors identified were severe xeroderma, prolonged duration of hemodialysis, use of an arteriovenous fistula, and the presence of Beau's lines, whereas the use of oral antidiabetic medications appeared to be protective. A better understanding of the pathophysiology of pruritus in hemodialysis patients could help improve its management and enhance patient comfort.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"4482167"},"PeriodicalIF":1.9,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical Corticosteroid Phobia in Childhood Atopic Dermatitis: A Study Using the TOPICOP Score. 儿童特应性皮炎的局部皮质类固醇恐惧症:一项使用TOPICOP评分的研究。
IF 1.9 Q3 DERMATOLOGY Pub Date : 2026-03-06 eCollection Date: 2026-01-01 DOI: 10.1155/drp/7996688
Mateja Starbek Zorko, Vid Bukovec, Tanja Fantulin

Background: Topical corticosteroid phobia (CSP) is a significant barrier to the effective treatment of atopic dermatitis (AD). This is the first study to evaluate the CSP prevalence among parents of children with AD in Slovenia and to identify contributing factors.

Methods: We conducted a cross-sectional study between March 2021 and December 2023. Parents of children with dermatologist-confirmed AD, aged 3 months to 18 years, completed the validated TOPICOP questionnaire, supplemental questions and the (F)DLQI questionnaire. The SCORAD index was used to assess the severity of their children's AD disease. Statistical analyses included the Shapiro-Wilk test, two-tailed independent t-test, ANOVA, followed by Tukey post hoc testing and the Pearson correlation coefficient.

Results: Among 117 parents (81.2% mothers), the mean TOPICOP score was 48.2% (SD 15.1). Fear was the highest-scoring TOPICOP domain (53.7%). CSP was significantly higher in parents of children with more severe AD based on SCORAD (p = 0.033) and in families with higher (F)DLQI scores (r = 0.311, p = 0.002). Notably, our results suggest that parents of children in single-parent households had significantly higher CSP (p = 0.035), a novel finding that warrants cautious interpretation due to the small subgroup size. Information obtained online about the potential dangers of topical corticosteroids (TCS) correlated with higher CSP (p < 0.001).

Conclusion: CSP is prevalent among Slovenian parents of children with AD and is particularly pronounced in cases of more severe disease and single-parent households, a novel and previously undescribed finding. Given that CSP is often influenced by nonmedical information sources, structured education and support by all healthcare providers is essential.

背景:局部皮质类固醇恐惧症(CSP)是特应性皮炎(AD)有效治疗的一个重要障碍。这是第一个评估斯洛文尼亚AD患儿父母CSP患病率并确定影响因素的研究。方法:我们在2021年3月至2023年12月期间进行了横断面研究。3个月至18岁皮肤科医生确诊的AD患儿的家长完成了经验证的TOPICOP问卷、补充问题和(F)DLQI问卷。使用SCORAD指数评估其子女AD疾病的严重程度。统计分析包括Shapiro-Wilk检验、双尾独立t检验、方差分析、Tukey事后检验和Pearson相关系数。结果117名家长中,母亲占81.2%,TOPICOP评分平均为48.2% (SD 15.1)。恐惧是TOPICOP得分最高的域(53.7%)。基于SCORAD的重度AD患儿家长的CSP显著高于(p = 0.033)和DLQI评分较高的家庭(r = 0.311, p = 0.002)。值得注意的是,我们的结果表明,单亲家庭中孩子的父母具有显著更高的CSP (p = 0.035),由于亚组规模较小,这一新发现需要谨慎解释。在线获得的关于局部皮质类固醇(TCS)潜在危险的信息与较高的CSP相关(p < 0.001)。结论:CSP在斯洛文尼亚患有AD儿童的父母中普遍存在,在疾病更严重的情况下和单亲家庭中尤为明显,这是一个新的和以前未描述过的发现。鉴于CSP经常受到非医疗信息源的影响,所有医疗保健提供者的结构化教育和支持至关重要。
{"title":"Topical Corticosteroid Phobia in Childhood Atopic Dermatitis: A Study Using the TOPICOP Score.","authors":"Mateja Starbek Zorko, Vid Bukovec, Tanja Fantulin","doi":"10.1155/drp/7996688","DOIUrl":"10.1155/drp/7996688","url":null,"abstract":"<p><strong>Background: </strong>Topical corticosteroid phobia (CSP) is a significant barrier to the effective treatment of atopic dermatitis (AD). This is the first study to evaluate the CSP prevalence among parents of children with AD in Slovenia and to identify contributing factors.</p><p><strong>Methods: </strong>We conducted a cross-sectional study between March 2021 and December 2023. Parents of children with dermatologist-confirmed AD, aged 3 months to 18 years, completed the validated TOPICOP questionnaire, supplemental questions and the (F)DLQI questionnaire. The SCORAD index was used to assess the severity of their children's AD disease. Statistical analyses included the Shapiro-Wilk test, two-tailed independent <i>t</i>-test, ANOVA, followed by Tukey post hoc testing and the Pearson correlation coefficient.</p><p><strong>Results: </strong>Among 117 parents (81.2% mothers), the mean TOPICOP score was 48.2% (SD 15.1). Fear was the highest-scoring TOPICOP domain (53.7%). CSP was significantly higher in parents of children with more severe AD based on SCORAD (<i>p</i> = 0.033) and in families with higher (F)DLQI scores (<i>r</i> = 0.311, <i>p</i> = 0.002). Notably, our results suggest that parents of children in single-parent households had significantly higher CSP (<i>p</i> = 0.035), a novel finding that warrants cautious interpretation due to the small subgroup size. Information obtained online about the potential dangers of topical corticosteroids (TCS) correlated with higher CSP (<i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>CSP is prevalent among Slovenian parents of children with AD and is particularly pronounced in cases of more severe disease and single-parent households, a novel and previously undescribed finding. Given that CSP is often influenced by nonmedical information sources, structured education and support by all healthcare providers is essential.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"7996688"},"PeriodicalIF":1.9,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12966341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Tecar Therapy in the Treatment of Skin Flaccidity and Localized Abdominal Fat-Clinical and Controlled Study. Tecar疗法治疗皮肤松弛和局部腹部脂肪的临床与对照研究。
IF 1.9 Q3 DERMATOLOGY Pub Date : 2026-02-23 eCollection Date: 2026-01-01 DOI: 10.1155/drp/5531539
Stephani de Almeida, Isabella Benatti Santiago, Cintia Cristina Santi Martignago, Michele Akemi Nishioka, Patricia Brassolatti, Jéssica Helena Franco Dorigatti, Fabiele Chieregato, Ana Carolina Araruna Alves, Stephany Luanna Queiroga Farias, Patricia Froes Meyer, José Ricardo de Souza

It is known that when an electrical stimulus is greater than 10 kHz, our body converts this electrical energy into thermal energy, and due to this fact, one of the therapies that has been showing good results is therapeutic, capacitive, and resistive energy transfer (tecar therapy), but there is still little evidence about its action on area of aesthetics. Therefore, the objective of this study was to evaluate the safety and efficacy of tecar therapy for the reduction of localized fat and improvement of skin flaccidity in the abdomen region. A controlled clinical trial was carried out with 48 women equally divided into 2 distinct groups, with (G-1) received treatment with tecar therapy and (G-2) considered the control. Ten treatment sessions were performed once a week. The volunteers were evaluated at three different times using anthropometric data, adipometry, and ultrasound (US), in addition to histological analysis of the adipose tissue performed on one of the volunteers. In the results of the adipometry and US, a decrease was observed both in the comparison between the groups and between the baseline and the end of the treatment for the supra and infra umbilical region. In the histological analysis, it was observed that the G1 showed positive markers for moderate chronic inflammation, indicating degeneration of the adipose tissue with a large number of fibroblasts and newly formed blood vessels in the integumentary tissue. With this, it was possible to conclude that tecar therapy proved to be a safe and effective resource in the treatment of sagging skin and reduction of superficial adipose tissue. Trial Registration: ClinicalTrials.gov identifier: NCT05020054.

众所周知,当电刺激大于10khz时,我们的身体将这种电能转化为热能,由于这一事实,一种已经显示出良好效果的疗法是治疗性、电容性和电阻性能量转移(tecar疗法),但它对美学领域的作用仍然很少有证据。因此,本研究的目的是评估car治疗减少腹部局部脂肪和改善腹部皮肤松弛的安全性和有效性。对48名妇女进行对照临床试验,将其平均分为2个不同的组,其中(G-1)接受tecar治疗,(G-2)作为对照组。每周进行10次治疗。除了对其中一名志愿者的脂肪组织进行组织学分析外,研究人员还在三个不同的时间对志愿者进行了人体测量数据、脂肪测量和超声波(US)的评估。在脂肪测量和US的结果中,在两组之间的比较以及在基线和脐上和脐下区域治疗结束之间观察到减少。在组织学分析中,G1显示中度慢性炎症阳性标记,表明脂肪组织变性,皮下组织有大量成纤维细胞和新形成的血管。由此可以得出结论,汽车治疗被证明是一种安全有效的治疗皮肤松弛和减少表面脂肪组织的资源。试验注册:ClinicalTrials.gov标识符:NCT05020054。
{"title":"Effect of Tecar Therapy in the Treatment of Skin Flaccidity and Localized Abdominal Fat-Clinical and Controlled Study.","authors":"Stephani de Almeida, Isabella Benatti Santiago, Cintia Cristina Santi Martignago, Michele Akemi Nishioka, Patricia Brassolatti, Jéssica Helena Franco Dorigatti, Fabiele Chieregato, Ana Carolina Araruna Alves, Stephany Luanna Queiroga Farias, Patricia Froes Meyer, José Ricardo de Souza","doi":"10.1155/drp/5531539","DOIUrl":"https://doi.org/10.1155/drp/5531539","url":null,"abstract":"<p><p>It is known that when an electrical stimulus is greater than 10 kHz, our body converts this electrical energy into thermal energy, and due to this fact, one of the therapies that has been showing good results is therapeutic, capacitive, and resistive energy transfer (tecar therapy), but there is still little evidence about its action on area of aesthetics. Therefore, the objective of this study was to evaluate the safety and efficacy of tecar therapy for the reduction of localized fat and improvement of skin flaccidity in the abdomen region. A controlled clinical trial was carried out with 48 women equally divided into 2 distinct groups, with (G-1) received treatment with tecar therapy and (G-2) considered the control. Ten treatment sessions were performed once a week. The volunteers were evaluated at three different times using anthropometric data, adipometry, and ultrasound (US), in addition to histological analysis of the adipose tissue performed on one of the volunteers. In the results of the adipometry and US, a decrease was observed both in the comparison between the groups and between the baseline and the end of the treatment for the supra and infra umbilical region. In the histological analysis, it was observed that the G1 showed positive markers for moderate chronic inflammation, indicating degeneration of the adipose tissue with a large number of fibroblasts and newly formed blood vessels in the integumentary tissue. With this, it was possible to conclude that tecar therapy proved to be a safe and effective resource in the treatment of sagging skin and reduction of superficial adipose tissue. <b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT05020054.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"5531539"},"PeriodicalIF":1.9,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12927974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147282757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Associated With Quality of Life and Treatment Practice Among Melasma Patients in Nepal. 尼泊尔黄褐斑患者生活质量及治疗实践相关因素
IF 1.9 Q3 DERMATOLOGY Pub Date : 2026-02-09 eCollection Date: 2026-01-01 DOI: 10.1155/drp/6380885
Samiksha Pokhrel, Sabina Sankhi, Shishir Paudel, Anisha Chalise, Nirmal Raj Marasine

Background: Melasma is chronic, acquired hypermelanosis that commonly appears on sun-exposed areas of the skin. Although it is asymptomatic, it can significantly affect patients' psychosocial and emotional well-being, ultimately reducing their quality of life. This study aimed to assess the factors associated with quality of life and treatment practices among melasma patients in Nepal.

Methods: A hospital-based cross-sectional study was conducted among 174 melasma patients visiting Nepal Skin Hospital, Kathmandu, from March to August 2023. The Melasma Area and Severity Index (MASI) score and the Melasma Quality of Life (MELASQoL) scale were used to evaluate melasma severity and quality of life, respectively. Statistical analyses included descriptive statistics, independent t-tests, one-way ANOVA, and multiple linear regression to identify factors associated with quality of life among women with melasma.

Results: The mean (±SD) MELASQoL score was 51.89. Most participants reported feeling frustrated (81.5%), embarrassed (78.8%), depressed (95.40%), and less productive (83.9%) due to melasma. Female gender, illiteracy, both current and previous OCP use, women with multiple pregnancies, lighter skin Types (III and IV), longer disease duration, and moderate MASI scores were significantly associated with higher MELASQoL values (p < 0.05). Sunscreen (97.7%) was the most prescribed treatment, followed by tranexamic acid (78.7%), hydroquinone (76.4%), antioxidants (71.3%), and chemical peels (69.0%).

Conclusion: Melasma has a significant psychosocial impact on affected individuals in Nepal. Disease severity, use of oral contraceptive pills, number of pregnancies, disease duration, education, and skin type significantly influenced quality of life. The strong association between disease severity and MELASQoL underscores the importance of integrating psychosocial assessment into clinical management. Sunscreen followed by tranexamic acid, hydroquinone, antioxidants, chemical peels, multivitamins, and retinoids was the predominant treatment approaches.

背景:黄褐斑是一种慢性的、获得性的黑色素过多症,通常出现在暴露在阳光下的皮肤上。虽然它是无症状的,但它可以显著影响患者的社会心理和情感健康,最终降低他们的生活质量。本研究旨在评估与尼泊尔黄褐斑患者的生活质量和治疗实践相关的因素。方法:对2023年3月至8月在加德满都尼泊尔皮肤医院就诊的174例黄褐斑患者进行了以医院为基础的横断面研究。采用黄褐斑面积和严重程度指数(MASI)评分和黄褐斑生活质量(MELASQoL)量表分别评价黄褐斑严重程度和生活质量。统计分析包括描述性统计、独立t检验、单因素方差分析和多元线性回归,以确定与黄褐斑妇女生活质量相关的因素。结果:MELASQoL平均(±SD)评分为51.89。大多数参与者报告说,由于黄褐斑,他们感到沮丧(81.5%)、尴尬(78.8%)、沮丧(95.40%)和效率低下(83.9%)。女性性别、文盲、当前和既往使用OCP、多次妊娠、肤色较浅(III型和IV型)、病程较长、MASI评分中等与较高的MELASQoL值显著相关(p < 0.05)。防晒(97.7%)是最常用的治疗方法,其次是氨甲环酸(78.7%)、对苯二酚(76.4%)、抗氧化剂(71.3%)和化学换肤(69.0%)。结论:黄褐斑对尼泊尔患者有显著的社会心理影响。疾病严重程度、口服避孕药的使用、怀孕次数、疾病持续时间、教育程度和皮肤类型显著影响生活质量。疾病严重程度与MELASQoL之间的强烈关联强调了将社会心理评估纳入临床管理的重要性。防晒霜、氨甲环酸、对苯二酚、抗氧化剂、化学换肤、多种维生素和类维生素a是主要的治疗方法。
{"title":"Factors Associated With Quality of Life and Treatment Practice Among Melasma Patients in Nepal.","authors":"Samiksha Pokhrel, Sabina Sankhi, Shishir Paudel, Anisha Chalise, Nirmal Raj Marasine","doi":"10.1155/drp/6380885","DOIUrl":"10.1155/drp/6380885","url":null,"abstract":"<p><strong>Background: </strong>Melasma is chronic, acquired hypermelanosis that commonly appears on sun-exposed areas of the skin. Although it is asymptomatic, it can significantly affect patients' psychosocial and emotional well-being, ultimately reducing their quality of life. This study aimed to assess the factors associated with quality of life and treatment practices among melasma patients in Nepal.</p><p><strong>Methods: </strong>A hospital-based cross-sectional study was conducted among 174 melasma patients visiting Nepal Skin Hospital, Kathmandu, from March to August 2023. The Melasma Area and Severity Index (MASI) score and the Melasma Quality of Life (MELASQoL) scale were used to evaluate melasma severity and quality of life, respectively. Statistical analyses included descriptive statistics, independent <i>t</i>-tests, one-way ANOVA, and multiple linear regression to identify factors associated with quality of life among women with melasma.</p><p><strong>Results: </strong>The mean (±SD) MELASQoL score was 51.89. Most participants reported feeling frustrated (81.5%), embarrassed (78.8%), depressed (95.40%), and less productive (83.9%) due to melasma. Female gender, illiteracy, both current and previous OCP use, women with multiple pregnancies, lighter skin Types (III and IV), longer disease duration, and moderate MASI scores were significantly associated with higher MELASQoL values (<i>p</i> < 0.05). Sunscreen (97.7%) was the most prescribed treatment, followed by tranexamic acid (78.7%), hydroquinone (76.4%), antioxidants (71.3%), and chemical peels (69.0%).</p><p><strong>Conclusion: </strong>Melasma has a significant psychosocial impact on affected individuals in Nepal. Disease severity, use of oral contraceptive pills, number of pregnancies, disease duration, education, and skin type significantly influenced quality of life. The strong association between disease severity and MELASQoL underscores the importance of integrating psychosocial assessment into clinical management. Sunscreen followed by tranexamic acid, hydroquinone, antioxidants, chemical peels, multivitamins, and retinoids was the predominant treatment approaches.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"6380885"},"PeriodicalIF":1.9,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12886184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146164553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological and Clinical Profile of Fixed Pigmented Erythema at the Departmental University Hospital Center Borgou/Alibori (Benin). Borgou/Alibori大学医院中心(贝宁)固定色素红斑的流行病学和临床概况
IF 1.9 Q3 DERMATOLOGY Pub Date : 2026-02-02 eCollection Date: 2026-01-01 DOI: 10.1155/drp/9911682
Fabrice Akpadjan, Laura Dotsop, Nadège Agbessi, Christiane Koudoukpo

Introduction: Fixed pigmented erythema (FPE) is a common toxidermia characterized by the appearance of one or more annular, erythematous and hyperpigmented spots, following the systemic administration of a drug. The main aim of this study was to describe the epidemiological and clinical aspects of fixed pigmented erythema at the Departmental University Hospital Center Borgou/Alibori (DUHC-B/A) from 2009 to 2022.

Methods: This was a descriptive cross-sectional study with retrospective data collection, based on the records of patients seen in the Dermatology-Venerology Unit for FPE. Initially, all files bearing the diagnosis of toxidermia were identified; then, those with the diagnosis of FPE with usable data were retained. Data were entered using EpiData 3.1 and analyzed using EpiData Analysis.

Results: Sixty-four patients were enrolled during the study period. The prevalence of FPE was 0.73%, with a male predominance. The most common drug identified was cotrimoxazole, followed by paracetamol and quinine. Over half of the patients (52.9%) were self-medicating.

Conclusion: Although FPE occurs rarely, it remains the most frequent toxidermia at the DUHC-B/A. It can be severe in its generalized bullous form. Avoiding the practice of self-medication could help reduce its prevalence.

简介:固定色素性红斑(FPE)是一种常见的氧化症,其特征是在全身给药后出现一个或多个环形红斑和色素沉着斑。本研究的主要目的是描述2009年至2022年在Borgou/Alibori院系大学医院中心(DUHC-B/A)发生的固定色素红斑的流行病学和临床方面。方法:这是一项描述性横断面研究,回顾性数据收集,基于在皮肤性病科就诊的FPE患者的记录。最初,所有诊断为氧化血症的档案都被确定;然后,保留那些诊断为FPE且有可用数据的患者。使用EpiData 3.1录入数据,并使用EpiData Analysis进行分析。结果:研究期间共纳入64例患者。FPE患病率为0.73%,以男性为主。最常见的药物是复方新诺明,其次是扑热息痛和奎宁。超过一半(52.9%)的患者自行用药。结论:虽然FPE很少发生,但它仍然是DUHC-B/A最常见的氧化血症。它可以是严重的,其广泛的大泡形式。避免自我用药可以帮助减少其患病率。
{"title":"Epidemiological and Clinical Profile of Fixed Pigmented Erythema at the Departmental University Hospital Center Borgou/Alibori (Benin).","authors":"Fabrice Akpadjan, Laura Dotsop, Nadège Agbessi, Christiane Koudoukpo","doi":"10.1155/drp/9911682","DOIUrl":"10.1155/drp/9911682","url":null,"abstract":"<p><strong>Introduction: </strong>Fixed pigmented erythema (FPE) is a common toxidermia characterized by the appearance of one or more annular, erythematous and hyperpigmented spots, following the systemic administration of a drug. The main aim of this study was to describe the epidemiological and clinical aspects of fixed pigmented erythema at the Departmental University Hospital Center Borgou/Alibori (DUHC-B/A) from 2009 to 2022.</p><p><strong>Methods: </strong>This was a descriptive cross-sectional study with retrospective data collection, based on the records of patients seen in the Dermatology-Venerology Unit for FPE. Initially, all files bearing the diagnosis of toxidermia were identified; then, those with the diagnosis of FPE with usable data were retained. Data were entered using EpiData 3.1 and analyzed using EpiData Analysis.</p><p><strong>Results: </strong>Sixty-four patients were enrolled during the study period. The prevalence of FPE was 0.73%, with a male predominance. The most common drug identified was cotrimoxazole, followed by paracetamol and quinine. Over half of the patients (52.9%) were self-medicating.</p><p><strong>Conclusion: </strong>Although FPE occurs rarely, it remains the most frequent toxidermia at the DUHC-B/A. It can be severe in its generalized bullous form. Avoiding the practice of self-medication could help reduce its prevalence.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"9911682"},"PeriodicalIF":1.9,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12862420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fibroblast Dynamics in Keloid Pathogenesis: Unraveling Cellular Crosstalk and Novel Therapeutic Targets. 瘢痕疙瘩发病过程中的成纤维细胞动力学:揭示细胞串扰和新的治疗靶点。
IF 1.9 Q3 DERMATOLOGY Pub Date : 2026-01-27 eCollection Date: 2026-01-01 DOI: 10.1155/drp/2528205
Ziad Alkouz, Ala'a Al Suwait, Lian Zhang, Rehab Alhejairi, Freddy Gahimbare, Mahmoud Qalalwa, Bin Yang

Keloid scars represent a complex fibroproliferative disorder characterized by abnormal wound healing and excessive collagen deposition. Central to keloid pathogenesis are dynamic fibroblast populations that undergo extensive phenotypic transitions, including heterogeneous subpopulation differentiation, enhanced migration, myofibroblast transdifferentiation, and sustained activation states. This review examines fibroblast dynamics as the central orchestrator of keloid formation, analyzing how these cells interact with keratinocytes, immune cells, endothelial cells, and melanocytes to drive pathological scarring. We focus on key signaling pathways that directly regulate fibroblast function, including TGF-β/Smad, VEGF, Wnt, and emerging regulators such as miR-3606-3p that integrate multiple fibrotic cascades. Current therapeutic approaches show variable efficacy, with surgical excision alone resulting in 45%-100% recurrence rates, while combination therapies incorporating radiation, intralesional injections, and novel molecular targets achieve improved outcomes. Emerging strategies include COX-2 inhibition for dual antiproliferative and proapoptotic effects on keloid fibroblasts, stem cell therapies, and precision medicine approaches based on molecular profiling. Through deeper understanding of fibroblast dynamics and their regulatory networks, more effective therapeutic strategies can be developed to improve patient outcomes and quality of life.

瘢痕疙瘩是一种复杂的纤维增生性疾病,其特征是伤口愈合异常和过多的胶原沉积。瘢痕疙瘩发病的核心是动态的成纤维细胞群,它们经历了广泛的表型转变,包括异质亚群分化、增强的迁移、肌成纤维细胞转分化和持续的激活状态。本文综述了成纤维细胞动力学作为瘢痕疙瘩形成的中心协调者,分析了这些细胞如何与角质形成细胞、免疫细胞、内皮细胞和黑素细胞相互作用以驱动病理性瘢痕形成。我们专注于直接调节成纤维细胞功能的关键信号通路,包括TGF-β/Smad, VEGF, Wnt以及整合多种纤维化级联反应的新兴调节因子miR-3606-3p。目前的治疗方法显示出不同的疗效,单纯的手术切除导致45%-100%的复发率,而结合放射、病灶内注射和新分子靶点的联合治疗可以改善结果。新兴的策略包括COX-2抑制对瘢痕疙瘩成纤维细胞的双重抗增殖和促凋亡作用,干细胞治疗和基于分子谱的精准医学方法。通过对成纤维细胞动力学及其调控网络的深入了解,可以制定更有效的治疗策略,以改善患者的预后和生活质量。
{"title":"Fibroblast Dynamics in Keloid Pathogenesis: Unraveling Cellular Crosstalk and Novel Therapeutic Targets.","authors":"Ziad Alkouz, Ala'a Al Suwait, Lian Zhang, Rehab Alhejairi, Freddy Gahimbare, Mahmoud Qalalwa, Bin Yang","doi":"10.1155/drp/2528205","DOIUrl":"https://doi.org/10.1155/drp/2528205","url":null,"abstract":"<p><p>Keloid scars represent a complex fibroproliferative disorder characterized by abnormal wound healing and excessive collagen deposition. Central to keloid pathogenesis are dynamic fibroblast populations that undergo extensive phenotypic transitions, including heterogeneous subpopulation differentiation, enhanced migration, myofibroblast transdifferentiation, and sustained activation states. This review examines fibroblast dynamics as the central orchestrator of keloid formation, analyzing how these cells interact with keratinocytes, immune cells, endothelial cells, and melanocytes to drive pathological scarring. We focus on key signaling pathways that directly regulate fibroblast function, including TGF-β/Smad, VEGF, Wnt, and emerging regulators such as miR-3606-3p that integrate multiple fibrotic cascades. Current therapeutic approaches show variable efficacy, with surgical excision alone resulting in 45%-100% recurrence rates, while combination therapies incorporating radiation, intralesional injections, and novel molecular targets achieve improved outcomes. Emerging strategies include COX-2 inhibition for dual antiproliferative and proapoptotic effects on keloid fibroblasts, stem cell therapies, and precision medicine approaches based on molecular profiling. Through deeper understanding of fibroblast dynamics and their regulatory networks, more effective therapeutic strategies can be developed to improve patient outcomes and quality of life.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"2528205"},"PeriodicalIF":1.9,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146092432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prurigo Pigmentosa Following Bariatric Surgery: A Comprehensive Clinicopathological Review. 减肥手术后色素性痒疹:综合临床病理回顾。
IF 1.9 Q3 DERMATOLOGY Pub Date : 2026-01-09 eCollection Date: 2026-01-01 DOI: 10.1155/drp/1993385
Khalid Nabil Nagshabandi, Abdulrahman M Shadid, Abdulah Abdulsalam Almazro, Asem Shadid, Suad Shadid, Lamia Alakrash

Prurigo pigmentosa (PP) is a rare inflammatory dermatosis first described in 1971 by Nagashima, classically predominantly affecting young women, particularly those of East Asian descent. Clinically, PP presents with pruritic, erythematous papules, which eventually form a reticulated pattern and resolve into post-inflammatory hyperpigmentation. The exact pathogenesis of PP remains unclear, but it is frequently linked to ketosis-inducing conditions, including strict dieting, fasting, and metabolic changes, such as those observed in diabetic ketoacidosis or anorexia nervosa. In recent years, PP has been increasingly reported in patients undergoing bariatric surgery, likely due to the rapid weight loss and subsequent ketosis that often follow these procedures. This review aims to take a closer and deeper look at the emerging connection between PP and bariatric surgery, particularly laparoscopic sleeve gastrectomy.

色素性痒疹(Prurigo pigmentosa, PP)是一种罕见的炎症性皮肤病,由Nagashima于1971年首次描述,通常主要影响年轻女性,特别是东亚血统的女性。临床上,PP表现为瘙痒性红斑丘疹,最终形成网状结构,并消退为炎症后色素沉着。PP的确切发病机制尚不清楚,但它通常与酮症诱导条件有关,包括严格的节食、禁食和代谢变化,如糖尿病酮症酸中毒或神经性厌食症。近年来,PP在接受减肥手术的患者中越来越多地被报道,可能是由于这些手术后体重迅速减轻和随后的酮症。本综述旨在更深入地探讨PP与减肥手术之间的联系,特别是腹腔镜袖胃切除术。
{"title":"Prurigo Pigmentosa Following Bariatric Surgery: A Comprehensive Clinicopathological Review.","authors":"Khalid Nabil Nagshabandi, Abdulrahman M Shadid, Abdulah Abdulsalam Almazro, Asem Shadid, Suad Shadid, Lamia Alakrash","doi":"10.1155/drp/1993385","DOIUrl":"10.1155/drp/1993385","url":null,"abstract":"<p><p>Prurigo pigmentosa (PP) is a rare inflammatory dermatosis first described in 1971 by Nagashima, classically predominantly affecting young women, particularly those of East Asian descent. Clinically, PP presents with pruritic, erythematous papules, which eventually form a reticulated pattern and resolve into post-inflammatory hyperpigmentation. The exact pathogenesis of PP remains unclear, but it is frequently linked to ketosis-inducing conditions, including strict dieting, fasting, and metabolic changes, such as those observed in diabetic ketoacidosis or anorexia nervosa. In recent years, PP has been increasingly reported in patients undergoing bariatric surgery, likely due to the rapid weight loss and subsequent ketosis that often follow these procedures. This review aims to take a closer and deeper look at the emerging connection between PP and bariatric surgery, particularly laparoscopic sleeve gastrectomy.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"1993385"},"PeriodicalIF":1.9,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12789810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thymoquinone Inhibits Proliferation and Induces Apoptosis in Immortalized Keratinocytes via Upregulation of p53 Expression. 百里醌通过上调p53表达抑制永生化角质形成细胞增殖和诱导凋亡。
IF 1.9 Q3 DERMATOLOGY Pub Date : 2025-12-04 eCollection Date: 2025-01-01 DOI: 10.1155/drp/9764336
Somaye Karimi, Narges Fallahi, Seyedeh Sindokht Hosseini, Mohammad Fereidouni, Fahime Ghasemi, Atena Mansouri, Nafiseh Erfanian, Mehdi Shakibaie, Mitra Rafiee

Introduction: Psoriasis, as a common inflammatory skin disease, is characterized by hyperproliferation of epidermal keratinocytes and induction of an inflammatory response. Apoptosis induction and prevention of the proliferation of keratinocytes can help to treat and manage this disease. Thymoquinone (TQ), a bioactive compound with antioxidant and anti-inflammatory properties, has also been reported as a natural antitumor agent. This study aimed to evaluate the effects of TQ on proliferation and apoptosis in human keratinocyte cells (HaCaT).

Methods: HaCaT cells were treated with increasing concentrations of TQ (1, 2, 4, 6, 8, 16, 32, and 64 μg/mL), and cell viability was assessed using the MTT assay. Apoptosis was analyzed via flow cytometry using Annexin V-FITC/PI staining. Expression levels of p53, Bax, and BCL-xl genes were measured by real-time PCR.

Results: TQ significantly reduced cell viability in a dose-dependent manner, with an IC50 of 11.64 μg/mL after 72 h. Flow cytometry revealed a marked increase in early apoptotic cells following treatment with 8 μg/mL TQ (41.00% ± 5.04%) compared to control (17.8% ± 2.26%, P ≤ 0.001). Gene expression analysis showed significant upregulation of p53, while Bax and BCL-xl levels showed no significant changes.

Conclusion: TQ induces apoptosis in human HaCaT cells primarily through p53-dependent pathways, suggesting its potential as a therapeutic agent for skin-related disorders.

简介:银屑病是一种常见的炎症性皮肤病,其特征是表皮角质形成细胞过度增生并诱导炎症反应。诱导凋亡和防止角质形成细胞增殖有助于治疗和控制这种疾病。百里醌(TQ)是一种具有抗氧化和抗炎特性的生物活性化合物,也是一种天然的抗肿瘤药物。本研究旨在探讨TQ对人角质形成细胞(HaCaT)增殖和凋亡的影响。方法:增加TQ浓度(1、2、4、6、8、16、32、64 μg/mL)处理HaCaT细胞,采用MTT法测定细胞活力。Annexin V-FITC/PI染色流式细胞术分析细胞凋亡。实时荧光定量PCR检测p53、Bax、BCL-xl基因的表达水平。结果:TQ显著降低细胞活力,且呈剂量依赖性,72 h后IC50为11.64 μg/mL。流式细胞术显示,8 μg/mL TQ处理后,早期凋亡细胞数量(41.00%±5.04%)明显高于对照组(17.8%±2.26%,P≤0.001)。基因表达分析显示p53显著上调,Bax和BCL-xl水平无明显变化。结论:TQ主要通过p53依赖通路诱导人HaCaT细胞凋亡,提示其作为皮肤相关疾病的治疗药物的潜力。
{"title":"Thymoquinone Inhibits Proliferation and Induces Apoptosis in Immortalized Keratinocytes via Upregulation of p53 Expression.","authors":"Somaye Karimi, Narges Fallahi, Seyedeh Sindokht Hosseini, Mohammad Fereidouni, Fahime Ghasemi, Atena Mansouri, Nafiseh Erfanian, Mehdi Shakibaie, Mitra Rafiee","doi":"10.1155/drp/9764336","DOIUrl":"10.1155/drp/9764336","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis, as a common inflammatory skin disease, is characterized by hyperproliferation of epidermal keratinocytes and induction of an inflammatory response. Apoptosis induction and prevention of the proliferation of keratinocytes can help to treat and manage this disease. Thymoquinone (TQ), a bioactive compound with antioxidant and anti-inflammatory properties, has also been reported as a natural antitumor agent. This study aimed to evaluate the effects of TQ on proliferation and apoptosis in human keratinocyte cells (HaCaT).</p><p><strong>Methods: </strong>HaCaT cells were treated with increasing concentrations of TQ (1, 2, 4, 6, 8, 16, 32, and 64 μg/mL), and cell viability was assessed using the MTT assay. Apoptosis was analyzed via flow cytometry using Annexin V-FITC/PI staining. Expression levels of p53, Bax, and BCL-xl genes were measured by real-time PCR.</p><p><strong>Results: </strong>TQ significantly reduced cell viability in a dose-dependent manner, with an IC50 of 11.64 μg/mL after 72 h. Flow cytometry revealed a marked increase in early apoptotic cells following treatment with 8 μg/mL TQ (41.00% ± 5.04%) compared to control (17.8% ± 2.26%, <i>P</i> ≤ 0.001). Gene expression analysis showed significant upregulation of p53, while Bax and BCL-xl levels showed no significant changes.</p><p><strong>Conclusion: </strong>TQ induces apoptosis in human HaCaT cells primarily through p53-dependent pathways, suggesting its potential as a therapeutic agent for skin-related disorders.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2025 ","pages":"9764336"},"PeriodicalIF":1.9,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12698257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145755667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iatrogenic Blepharoptosis: Multimodal Management and Treatment Technique With Botulinum Toxin Type A. 医源性上睑下垂:A型肉毒杆菌毒素的多模式管理和治疗技术。
IF 1.9 Q3 DERMATOLOGY Pub Date : 2025-10-17 eCollection Date: 2025-01-01 DOI: 10.1155/drp/8827594
Rengifo-Palacios Jaime Alberto, Macías-Arias Paola Andrea, Uribe-Posada Maria Paulina, Lopera-Botero Luisa
<p><strong>Blepharoptosis as an aesthetic complication: </strong>Eyelid ptosis, or blepharoptosis, following esthetic treatment of the upper third with botulinum toxin Type A (BoNT-A) is a complication with a variable incidence depending on the injector's experience. Among unexperienced injectors, it ranges from 2.5% to 5.4% and approximately 0.51% to 1% in experienced injectors. Blepharoptosis is commonly defined as an eyelid located between 1.5 and 2 mm below the scleral-corneal limbus. It occurs because of the local spread of botulinum toxin, affecting the levator palpebrae superioris muscle, one of the principal muscles for elevating the superior eyelid. It typically becomes evident 3-14 days after BoNT-A application and resolves spontaneously after approximately 3 months, once the toxin's effect subsides. Even though it resolves with time, it can cause great distress for the patient and the physician.</p><p><strong>Treatment modality: </strong>In turn, knowing the anatomy of the face in high detail will help the physician treat and prevent this complication, which can be avoided with correct training and application. Once it has happened, it is important to recognize the severity of the blepharoptosis (which is classified as mild, moderate, or severe), in order to decide whether to use oxymetazoline or apraclonidine eye drops, muscle exercises, vibrating devices, radiofrequency, and the latest option described with pretarsal BoNT-A application. Even though the treatment is challenging, and evidence is scarce, here we present a literature review and some clinical cases of successful treatment with pretarsal BoNT-A in iatrogenic blepharoptosis following esthetic treatment of the upper third.</p><p><strong>Objective: </strong>This review highlights the importance of facial anatomy knowledge to minimize potential complications associated with BoNT-A application. It also describes the clinical classification and management of iatrogenic blepharoptosis based on severity, with special emphasis on the pretarsal BoNT-A application technique.</p><p><strong>Methods of literature search: </strong>A literature search was conducted using electronic databases (PubMed, MEDLINE, Embase, and Google Scholar), focusing on upper third anatomy, prevention of iatrogenic blepharoptosis secondary to BoNT-A application, classification, and therapeutic options based on severity.</p><p><strong>Results: </strong>Iatrogenic eyelid ptosis after BoNT-A application results from the neurotoxin spreading to the levator palpebrae superioris muscle. Current therapeutic options include sympathomimetic eye drops, vibration therapy, facial exercises, radiofrequency, and pretarsal BoNT-A application. This review emphasizes anatomical knowledge, risk factors' identification, and anatomical landmarks to minimize complications. The pretarsal treatment technique for iatrogenic ptosis using BoNT-A is also detailed.</p><p><strong>Limitations: </strong>The limitations of this review consi
眼睑下垂作为美学并发症:A型肉毒毒素(BoNT-A)美容治疗后的上三分之一眼睑下垂或眼睑下垂是一种并发症,其发生率取决于注射者的经验。在没有经验的注射者中,其范围为2.5%至5.4%,在有经验的注射者中约为0.51%至1%。眼睑下垂通常定义为眼睑位于巩膜-角膜缘以下1.5 - 2mm。它的发生是由于肉毒杆菌毒素的局部扩散,影响提上睑肌,提上睑肌是提升上眼睑的主要肌肉之一。它通常在BoNT-A应用后3-14天变得明显,大约3个月后,一旦毒素的影响消退,它就会自发消退。尽管它会随着时间的推移而消退,但它会给病人和医生带来巨大的痛苦。治疗方式:反过来,对面部解剖结构的详细了解将有助于医生治疗和预防这种并发症,通过正确的训练和应用可以避免这种并发症。一旦发生上睑下垂,重要的是要认识到上睑下垂的严重程度(分为轻度、中度或重度),以便决定是否使用羟美唑啉或阿普拉定滴眼液、肌肉锻炼、振动装置、射频治疗,以及最新的睑前BoNT-A应用方法。尽管治疗是具有挑战性的,证据也很少,在这里,我们提出了一篇文献综述和一些成功治疗的临床病例,这些病例是在上三分之一的美学治疗后,使用睑前BoNT-A治疗医源性上睑下垂的。目的:本综述强调面部解剖知识的重要性,以尽量减少BoNT-A应用相关的潜在并发症。本文还介绍了医源性上睑下垂的临床分类和治疗方法,重点介绍了鼻窦前BoNT-A应用技术。文献检索方法:使用电子数据库(PubMed、MEDLINE、Embase和谷歌Scholar)进行文献检索,重点关注上三分之一解剖、BoNT-A应用继发医源性上睑下垂的预防、分类和基于严重程度的治疗方案。结果:BoNT-A应用后医源性上睑下垂是神经毒素扩散至提上睑肌所致。目前的治疗方案包括拟交感眼药水、振动疗法、面部运动、射频和鼻窦前BoNT-A应用。这篇综述强调解剖学知识,危险因素的识别和解剖学标志,以尽量减少并发症。本文还详细介绍了使用BoNT-A治疗医源性上睑下垂的睑前治疗技术。局限性:本综述的局限性包括患者数量非常有限;另一个限制是没有患者有严重的上睑下垂来证明治疗。结论:在训练有素的注射人员中,美观BoNT-A治疗后睑下垂是罕见的并发症。治疗选择的知识,包括鼻窦前BoNT-A注射技术,对于控制这种并发症至关重要,它会对审美和功能产生重大影响。
{"title":"Iatrogenic Blepharoptosis: Multimodal Management and Treatment Technique With Botulinum Toxin Type A.","authors":"Rengifo-Palacios Jaime Alberto, Macías-Arias Paola Andrea, Uribe-Posada Maria Paulina, Lopera-Botero Luisa","doi":"10.1155/drp/8827594","DOIUrl":"10.1155/drp/8827594","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Blepharoptosis as an aesthetic complication: &lt;/strong&gt;Eyelid ptosis, or blepharoptosis, following esthetic treatment of the upper third with botulinum toxin Type A (BoNT-A) is a complication with a variable incidence depending on the injector's experience. Among unexperienced injectors, it ranges from 2.5% to 5.4% and approximately 0.51% to 1% in experienced injectors. Blepharoptosis is commonly defined as an eyelid located between 1.5 and 2 mm below the scleral-corneal limbus. It occurs because of the local spread of botulinum toxin, affecting the levator palpebrae superioris muscle, one of the principal muscles for elevating the superior eyelid. It typically becomes evident 3-14 days after BoNT-A application and resolves spontaneously after approximately 3 months, once the toxin's effect subsides. Even though it resolves with time, it can cause great distress for the patient and the physician.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Treatment modality: &lt;/strong&gt;In turn, knowing the anatomy of the face in high detail will help the physician treat and prevent this complication, which can be avoided with correct training and application. Once it has happened, it is important to recognize the severity of the blepharoptosis (which is classified as mild, moderate, or severe), in order to decide whether to use oxymetazoline or apraclonidine eye drops, muscle exercises, vibrating devices, radiofrequency, and the latest option described with pretarsal BoNT-A application. Even though the treatment is challenging, and evidence is scarce, here we present a literature review and some clinical cases of successful treatment with pretarsal BoNT-A in iatrogenic blepharoptosis following esthetic treatment of the upper third.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;This review highlights the importance of facial anatomy knowledge to minimize potential complications associated with BoNT-A application. It also describes the clinical classification and management of iatrogenic blepharoptosis based on severity, with special emphasis on the pretarsal BoNT-A application technique.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods of literature search: &lt;/strong&gt;A literature search was conducted using electronic databases (PubMed, MEDLINE, Embase, and Google Scholar), focusing on upper third anatomy, prevention of iatrogenic blepharoptosis secondary to BoNT-A application, classification, and therapeutic options based on severity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Iatrogenic eyelid ptosis after BoNT-A application results from the neurotoxin spreading to the levator palpebrae superioris muscle. Current therapeutic options include sympathomimetic eye drops, vibration therapy, facial exercises, radiofrequency, and pretarsal BoNT-A application. This review emphasizes anatomical knowledge, risk factors' identification, and anatomical landmarks to minimize complications. The pretarsal treatment technique for iatrogenic ptosis using BoNT-A is also detailed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Limitations: &lt;/strong&gt;The limitations of this review consi","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2025 ","pages":"8827594"},"PeriodicalIF":1.9,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12552077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145376429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Mechanism and Research Progress of Skin Microbiota in Pathogenesis of Acne. 皮肤微生物群在痤疮发病中的作用机制及研究进展。
IF 1.9 Q3 DERMATOLOGY Pub Date : 2025-10-14 eCollection Date: 2025-01-01 DOI: 10.1155/drp/9910076
Xinwei Li, Juan Jin

Acne is a chronic inflammatory skin disease of the sebaceous unit of the facial hair follicle that occurs mainly in adolescence. The four major pathogenesis of acne are excessive secretion of sebum by sebaceous glands, abnormal keratosis of sebaceous glands in hair follicles, reproduction of skin microorganisms such as Cutibacterium acnes (C. acnes), and inflammatory reaction. Among the skin microbiota, C. acnes and Malassezia affect the secretion of sebaceous glands, mediate inflammation, and are closely related to the pathogenesis of acne. With the development of the theory of "Gut-skin axis," the role of intestinal microbiota and skin microecology in acne regulation has gradually become the focus of researchers. The purpose of this study is to investigate the influence of skin microbiota and the interaction between gut and skin on the pathogenesis of acne and to analyze the potential mechanism of skin microbiota during the pathogenesis of acne. It is expected that further understanding of skin microbiota (including its potential mechanism) will help clarify its role in acne and provide new ideas for the pathogenesis and clinical treatment of acne and other inflammatory skin diseases.

痤疮是一种主要发生在青春期的面部毛囊皮脂腺单位的慢性炎症性皮肤病。痤疮的四大发病机制是皮脂腺分泌皮脂过多、毛囊皮脂腺角化异常、痤疮角质杆菌(C. acnes)等皮肤微生物繁殖、炎症反应。在皮肤微生物群中,C. acnes和Malassezia影响皮脂腺分泌,介导炎症,与痤疮的发病密切相关。随着“肠皮轴”理论的发展,肠道菌群和皮肤微生态在痤疮调节中的作用逐渐成为研究者关注的焦点。本研究旨在探讨皮肤微生物群及肠道与皮肤的相互作用对痤疮发病的影响,并分析皮肤微生物群在痤疮发病中的潜在机制。进一步了解皮肤微生物群及其潜在机制,有助于阐明其在痤疮中的作用,为痤疮及其他炎症性皮肤病的发病机制和临床治疗提供新的思路。
{"title":"The Mechanism and Research Progress of Skin Microbiota in Pathogenesis of Acne.","authors":"Xinwei Li, Juan Jin","doi":"10.1155/drp/9910076","DOIUrl":"10.1155/drp/9910076","url":null,"abstract":"<p><p>Acne is a chronic inflammatory skin disease of the sebaceous unit of the facial hair follicle that occurs mainly in adolescence. The four major pathogenesis of acne are excessive secretion of sebum by sebaceous glands, abnormal keratosis of sebaceous glands in hair follicles, reproduction of skin microorganisms such as Cutibacterium acnes (<i>C. acnes</i>), and inflammatory reaction. Among the skin microbiota, <i>C. acnes</i> and <i>Malassezia</i> affect the secretion of sebaceous glands, mediate inflammation, and are closely related to the pathogenesis of acne. With the development of the theory of \"Gut-skin axis,\" the role of intestinal microbiota and skin microecology in acne regulation has gradually become the focus of researchers. The purpose of this study is to investigate the influence of skin microbiota and the interaction between gut and skin on the pathogenesis of acne and to analyze the potential mechanism of skin microbiota during the pathogenesis of acne. It is expected that further understanding of skin microbiota (including its potential mechanism) will help clarify its role in acne and provide new ideas for the pathogenesis and clinical treatment of acne and other inflammatory skin diseases.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2025 ","pages":"9910076"},"PeriodicalIF":1.9,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12539983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145344128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Dermatology Research and Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1